FDA OKs presurgical use of Roche's breast cancer drug Perjeta

10/1/2013 | Bloomberg · Reuters

The FDA approved the use of Roche Holding's Perjeta, or pertuzumab, to reduce tumor size before surgery in patients with HER2-positive, early-stage breast cancer. The drug would be used in combination with Roche's older breast cancer treatment Herceptin and chemotherapy. The approval makes Perjeta the first presurgical treatment for breast cancer.

View Full Article in:

Bloomberg · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX